The alfa pump® system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical ...

Ghent, BELGIUM – 17 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, ...

March 13, 2003 — Transjugular intrahepatic portosystemic shunts (TIPS) plus medical therapy is better than medical therapy alone in controlling ascites, but not in improving survival, hospitalization ...

PREVIOUS studies have indicated that in patients with cirrhosis the presence or absence of ascites can be explained by a consideration of hydrostatic and osmotic forces, and a similar analysis can be ...

The liver is a powerhouse that carries out many crucial functions in our body producing essential proteins, hormones and cholesterol. It acts as a filter, removing toxins from the food we eat. However ...

Ghent, Belgium – 23 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

ASCITES is a problem frequently encountered and often unsatisfactorily treated. An adjunct in the therapy of ascites has been tried in a limited number of cases and has seemed sufficiently helpful to ...

Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without ...

Malignant ascites can develop with late stage pancreatic cancer. Ascites involves the buildup of fluid in the abdomen. Doctors can drain the fluid to relieve symptoms, but fluid may return. Ascites ...

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic ...